Clinical trials: Chronic Hepatitis B Infections
Chronic Hepatitis B
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown.
- Trial name
- NCT04939441
- Testing
- Tenofovir alafenamide
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Jidong Jia
Chronic Hepatitis B, HBeAg Negative
Terminator 2 Register
All patients with chronic HBeAg negative hepatitis B treated with nucleos(t)ide analogues, who discontinue treatment based in the criteria outlined in the EASL hepatitis B guidelines shall be included in the present study.
- Trial name
- NCT03643172
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Hannover Medical School
Hepatitis B, Chronic
Drug Drug Interaction Study for EYP001 With Entecavir
This is a Phase 1, single-center, open-label, three subsequent dosing periods study to evaluate the drug-drug-interaction (DDI), pharmaco-kinetics (PK) and pharmacodynamics (PD), safety, and tolerability of a single dose of…
- Trial name
- NCT03469583
- Testing
- EYP001, Entecavir 1 MG
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Chronic Hepatitis C
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
This is a Phase 2, randomized, open-label exploratory study that will examine the antiviral efficacy, safety, and tolerability of Response guided treatment (RGT) with GS-5885 + GS-9451 + PEG/RBV (6 or 12 weeks), or Peginterferon…
- Trial name
- NCT01384383
- Testing
- GS-5885, GS-9451, RBV
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 248 people
- Sponsor
- Gilead Sciences
HBV/HCV Co-infection
A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection
This is an open label, randomized-controlled, comparative trial. HBV and HCV dually infected patients with negative hepatitis B e antigen (HBeAg) were enrolled in the study.
- Trial name
- NCT02339337
- Testing
- Abbreviation of treatment duration
- Volunteers
- 203 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis B
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
Patients with chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.
- Trial name
- NCT02604199
- Testing
- ARC-520 Injection, entecavir, tenofovir
- Where
- 16 sites in China, Germany and 1 more
- Volunteers
- 58 people
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis B Virus Infection
A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection
This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses in healthy volunteers (HV) and participants diagnosed with chronic hepatitis B…
- Trial name
- NCT03762681
- Testing
- RO7239958
- Where
- 14 sites in Bulgaria, Hong Kong and 5 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
- Trial name
- NCT00048945
- Testing
- PEGASYS
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 820 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis b
A Study of LP-128 Capsules in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LP-128 Capsules After Single- and Multiple-Dose in Healthy Subjects
- Trial name
- NCT05130567
- Testing
- LP-128 capsules
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Hepatitis B, Chronic Disease
Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program
The purpose of this clinical research study is to provide entecavir to subjects with chronic Hepatitis B infection who have failed or who have demonstrated intolerance of marketed therapies or for those in whom use of these…
- Trial name
- NCT00096811
- Testing
- Entecavir
- Where
- 5 sites in Israel
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
This study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the…
- Trial name
- NCT00057265
- Testing
- telbivudine or lamivudine
- Where
- 11 sites in United States, South Korea and 4 more
- Sponsor
- Novartis
Chronic Hepatitis B
A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002
This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, immunogenicity and preliminary efficacy of the YSHBV-002 in the treatment of CHB in adults ≥18 years…
- Trial name
- NCT06162299
- Testing
- YS-HBV-002
- Where
- Philippines
- Volunteers
- 16 people
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
Chronic Hepatitis B Virus (Hbv)
Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)
Background: People who were born outside of the country are the largest group of adults infected with chronic hepatitis B virus (HBV) in the US. HBV affects the liver.
- Trial name
- NCT05621304
- Where
- 2 sites in United States
- Volunteers
- 274 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B Virus (HBV)
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients
Hepatitis B virus (HBV) infection is a worldwide health problem. It has been proved that the persistence of HBV is associated with the failure to stimulate an efficient HBV-specific immune response.
- Trial name
- NCT04168333
- Testing
- T101 Group
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Chronic Hepatitis B
Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B
This randomized controlled trial is designed to evaluate safety, effectiveness and pharmacokinetic-pharmacodynamic (PK/PD) relationships associated with three different Nitazoxanide (NTZ) treatment regimens added to Tenofovir…
- Trial name
- NCT03905655
- Testing
- Nitazoxanide
- Where
- Singapore
- Volunteers
- 51 people
- Sponsor
- Romark Laboratories L.C.
HBeAg Positive Chronic Hepatitis B
Study on Antiviral Therapy for HBeAg-positive Chronic Hepatitis B Patients Aged 1-16 Years
The purpose of this study is to provide theoretical and real world evidence for the optimization of antiviral treatment by IFN combined with Nucleosides analog in HBeAg positive chronic hepatitis B patients aged 1-16 years，so…
- Trial name
- NCT04565262
- Testing
- NAs+IFN-α
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing 302 Hospital
Chronic Hepatitis B
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFNα in CHB patients
- Trial name
- HBV (NCT07135349)
- Testing
- BW-20507 with/without NUC, BW-20507 with/without NUC, Peg-IFNa
- Where
- 18 sites in China
- Volunteers
- 209 people
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
Hepatitis B, Chronic
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) changes from baseline for the treatment regimens of 24 weeks of JNJ-73763989 + 24 weeks of nucleos(t)ide analog (NA) + 12 or 24…
- Trial name
- PENGUIN-2 (NCT05005507)
- Testing
- JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 1 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis B, Chronic
A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine
A single center, open labeled phase I/IIa study to evaluate safety, tolerability and efficacy of a therapeutic hepatitis B vaccine in oral antiviral drug-treated chronic hepatitis B virus carriers
- Trial name
- NCT02693652
- Testing
- CVI-HBV-002
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Aribio Lab Co., Ltd.
Hepatitis B， Chronic, Hepatitis C
The HOPE Study: Characterizing Patients With Hepatitis B and C
This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C.
- Trial name
- NCT02995252
- Testing
- Blood draws, Tenofovir Alafenamide, Knowledge Index Questionnaire
- Where
- 2 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.